cAMP responsive element modulatorGenealiases: CREM-2 · ICER · hCREM-2
Q-omics provides the consensus-scored CREM profile across patient tissues and cancer cell-line models. CREM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CREM is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CREM RNA expression shows 18,782 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where CREM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CREM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CREM survival associations across molecular data types. CREM RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CREM RNA expression–survival associations across cancer types. High CREM expression shows unfavorable associations in UVM, ACC, KIRP, LGG, STAD and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CREM RNA expression.
This table summarizes CREM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CREM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CREM shows lower tumor expression in KICH, BLCA, THCA, UCEC and KIRC and higher tumor expression in HNSC. The KICH box plot shows higher CREM RNA expression in normal versus tumor tissue (log2 FC = −2.250, t-test p < 0.001).
This table shows molecular features associated with CREM in patient tissues and cancer cell lines. In patient samples, CREM shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CREM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
